Rezultati - Tsen‐Fang Tsai

Refine Results
  1. 1
    Updates on the Treatment of Erythrodermic Psoriasis

    Updates on the Treatment of Erythrodermic Psoriasis od Yang Lo, Tsen‐Fang Tsai

    Izdano 2021
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

    Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness od Ya‐Chu Tsai, Tsen‐Fang Tsai

    Izdano 2017
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    HLA-Cw1 and Psoriasis

    HLA-Cw1 and Psoriasis od Yi‐Wei Huang, Tsen‐Fang Tsai

    Izdano 2021
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center

    Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center od Yi‐Wei Huang, Tsen‐Fang Tsai

    Izdano 2021
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes

    Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes od Ya‐Chu Tsai, Tsen‐Fang Tsai

    Izdano 2022
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Topical egg yolk oil (4% cholesterol) and oral rosuvastatin for the treatment of disseminated superficial actinic porokeratosis

    Topical egg yolk oil (4% cholesterol) and oral rosuvastatin for the treatment of disseminated superficial actinic porokeratosis od Chang‐Yu Hsieh, Tsen‐Fang Tsai

    Izdano 2025
    Polni tekst
    Carta
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis

    Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis od Ya‐Chu Tsai, Chen‐Yiu Hung, Tsen‐Fang Tsai

    Izdano 2023
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    How Cells Die in Psoriasis?

    How Cells Die in Psoriasis? od Chung-Han Chen, Nan‐Lin Wu, Tsen‐Fang Tsai

    Izdano 2025
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Psoriasis and Co-morbidity

    Psoriasis and Co-morbidity od Mina Amin, Erica B. Lee, Tsen‐Fang Tsai, Jashin J. Wu

    Izdano 2020
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    Use of anti‐tumor necrosis factor‐α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan

    Use of anti‐tumor necrosis factor‐α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan od Yung‐Tsu Cho, Chien‐Hung CHEN, Hsien‐Yi Chiu, Tsen‐Fang Tsai

    Izdano 2011
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

    The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C od Hsien‐Yi Chiu, Chi‐Hau Chen, Ming‐Shiou Wu, Y.‐P. Cheng, Tsen‐Fang Tsai

    Izdano 2013
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

    Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement od Tzong-Yun Ger, Yu‐Huei Huang, Rosaline Chung‐Yee Hui, Tsen‐Fang Tsai, Hsien‐Yi Chiu

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp> trial

    Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp>... od Richard Langley, Tsen‐Fang Tsai, Susan Flavin, Michael Song, B. Randazzo, Y. Wasfi, Jingzhi Jiang, S. Li, L. Puig

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Psoriasis in Taiwan: From epidemiology to new treatments

    Psoriasis in Taiwan: From epidemiology to new treatments od Hsien‐Yi Chiu, Ting‐Shun Wang, Po-Hua Chen, Shao-Hsuan Hsu, Ya‐Chu Tsai, Tsen‐Fang Tsai

    Izdano 2018
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2

    Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2 od Mark C. Genovese, B. Combe, Joel M. Kremer, Tsen‐Fang Tsai, Frank Behrens, David H. Adams, Chin Lee, Lisa Kerr, Peter Nash

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial od Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, F. Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, R. You, M. Milutinovic

    Izdano 2015
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Inhibition of IL‐17A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis</i> infections

    Inhibition of IL‐17A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis</i> infections od Michael Kammüller, Tsen‐Fang Tsai, C.E.M. Griffiths, Nidhi Kapoor, Pappachan E. Kolattukudy, Dominique Brees, Salah‐Dine Chibout, Jorge Safi, Todd Fox

    Izdano 2017
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study

    Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study od Fernando Valenzuela, Neil J. Korman, Robert Bissonnette, Noémi Bakos, Tsen‐Fang Tsai, Melanie Harper, W.C. Ports, Huaming Tan, Anna M. Tallman, Hernán Valdez, Annie Gardner

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study

    Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study od Hsien‐Yi Chiu, Rosaline Chung‐Yee Hui, Yu-Huei Huang, Ruey-Yun Huang, Kai-Lung Chen, Ya‐Chu Tsai, Po-Ju Lai, Ting‐Shun Wang, Tsen‐Fang Tsai

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis

    Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis od Akimichi Morita, Siew Eng Choon, H. Bachelez, Milan J. Anadkat, Slaheddine Marrakchi, Min Zheng, Tsen‐Fang Tsai, H. Turki, Harry Hua, Sushmita Rajeswari, Christian Thoma, A. David Burden

    Izdano 2022
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: